Great meeting with so many inspiring talks last 2 days. Looking forward to the meeting next year! Photo with my supervisor Tara Roberts in front of our poster #TAS2018 #liquidbiopsy

Nicole Caixeiro presenting about the important work CONCERT Biobank is doing to help researchers across different sites. Thanks for helping with my research in the last few years #CONCERT #TCRW

Professor Paul de Souza, director of CONCERT talking about his experience and the challenges (and solutions) of setting up oncology phase 1 trial centre #CONCERT #TCRW

A/Prof Kieran Scott presenting the exciting preliminary result from Phase 0 prostate cancer trial on C2 novel prostate cancer drug #CONCERT #TCRW #LiverpoolHospital

Dr Lorraine Chantrill sharing her experience on the triumphs and pitfalls in setting up a clinical trials unit at TKCC #CONCERT #TCRW

Interesting talk by Dr Deme Karikios on his PhD research on the consequences of rising anti cancer drug costs Dr Deme Karikios #CONCERT #TCRW

Great talk by Dr Abhijit Pal, advanced trainee from Liverpool Hospital invited by CONCERT #TCRW to speak on the hot topic of anti cancer drug cost and how to help patients to make decision about unfunded high cost drugs Abhijit Pal

Vali presenting AURA3 resistance mechs by ctDNA by Guardant Health 12%osi & 20% non-shedders. For osi: loss of T790M esp del19s. C790x 14% esp L858R all were cis. METamp 19%. A new pie of resistance mechs. Underpowered for PFS assocts #ESMO18 #LCSM

Wonderfully clear and elegant presentation by Suresh S. Ramalingam, MD, FASCO at #ESMO18 on mechanisms of resistance to Osimertinib detected by ctDNA. MET amplification most common. ctDNA may underestimate MET amplification (vs tissue) and does not detect histology transformation #rebiopsy #LCSM

First phase 3 trial showing benefit of immunotherapy in first-line setting for metastatic TNBC! #ESMO18

Nice analysis of the Pacific data by Corinne Faivre-Finn with concomitant cisplatin-based chemoradiation as the best schedule and start Durvalumab asap after CT-RT ESMO - Eur. Oncology Marseille Immunopole #ESMO18 AP-HM - Hôpitaux Universitaires de Marseille

STAMPEDE arm with ADT+prostate RT in mHSPC -XRT to the primary improves failure free survival and OS in low burden disease. ADT will no longer be acceptable as the sole treatment for this patient group.Future Qs:surgery vs RT?N1M0 disease? #esmo18

Exciting work by @drkoonlee from Sydney Uni about CAR T cells in AML . Poster discussion by Dr Marion Subklewe #esmo2018

Avelumab+axitinib improves PFS in first line mRCC regardless of PDL-1 status and prognostic groups. But is this combo better than sequential treatment? OS data will be useful.

Excellent overview on the clinical utility of liquid biopsy with CTCs for solid cancer by Prof Klaus Pantel #ESMO2018

Excellent overview by Dr Tara Roberts at the inaugural WSU Western Cancer Research Forum regarding the exciting work we are doing in the lab.Tara Roberts #WSU #WesternU

Interesting and useful updates from Dr Sonia Yip NHMRC CTC regarding CTC trials at NHRMC CTC, and considerations prior to including CTC/ctDNA work in trials #TAS2019 nice to meet you finally in person today!

Is this an equitable model?

Thanks Geoff for sharing how you used humour in your lung cancer journey and for drawing a ‘funny but pretty’ portrait of me! Check out his new book! #ALCC2020 Lung Foundation Australia